Savara Inc.
SVRASavara Inc. (SVRA) is a clinical-stage pharmaceutical company focused on developing therapies for rare and ultra-rare respiratory diseases. The company's pipeline includes inhaled treatments aimed at conditions such as alveolar phospholipoproteinosis (PAP) and other rare pulmonary disorders. Savara's approach involves leveraging innovative drug delivery methods to address unmet medical needs in these specialized areas.
Company News
Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, will present at the 44th Annual J.P. Morgan Healthcare Conference. The company's lead program, MOLBREEVI, is a Phase 3 development treatment for autoimmune pulmonary alveolar proteinosis.
Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, will participate in upcoming healthcare investor conferences, hosting one-on-one meetings and fireside chats.
The Schall Law Firm is pursuing a class action lawsuit against Savara Inc. for allegedly making false and misleading statements about their BLA (Biologics License Application) for MOLBREEVI, which was deemed insufficient by the FDA and likely to require additional capital.
Rosen Law Firm alerts Savara Inc. investors about a securities class action lawsuit regarding potential misleading statements about a clinical trial's regulatory approval process, with a November 7, 2025 lead plaintiff deadline.
Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, will participate in upcoming healthcare investor conferences, hosting meetings and fireside chats to discuss their lead program MOLBREEVI.
